Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase III Study to Determine the Efficacy of a Taxane and Bevacizumab With or Without Capecitabine as First Line Chemotherapy in Patients With Metastatic Breast Cancer

NCT01200212 is registered in ClinicalTrials.gov with GBG Forschungs GmbH as lead sponsor.

NCT NCT01200212
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01200212 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase III Study to Determine the Efficacy of a Taxane and Bevacizumab With or Without Capecitabine as First Line Chemotherapy in Patients With Metastatic Breast Cancer
Lead sponsor
GBG Forschungs GmbH
Phase
Phase 3
Overall status
Terminated
Start date
July 31, 2009
Completion date
October 31, 2012
Enrollment
432 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer